



Press contact: Sal Braico, Flex Biomedical
(608) 213-8246, sbraico@flexbio.com
<http://www.flexbio.com>

Flex Biomedical to Present at Premiere Orthopedic Conference

FOR IMMEDIATE RELEASE

October 21, 2010, Madison, WI—Flex Biomedical, Inc., a privately-held biomedical company focused on developing novel treatments for orthopedic diseases today announces that company CEO, Sal Braico, was selected to present at the prestigious Musculoskeletal New Ventures Conference on October 26, 2010, in Memphis.

The eighth annual Musculoskeletal New Ventures Conference (<http://www.mnvc.org/>) features surgeons, venture capitalists, industry leaders, and researchers who share cutting-edge information in the dynamic field of orthopedic research.

Flex Biomedical, a Madison, Wis. company founded in 2007, is developing innovative treatments for orthopedic diseases. The company's lead product, the Flex Polymer™, is a synthetic polymer designed to treat osteoarthritis, an incurable, debilitating disease that affects 27 million people in the United States and 100 million people worldwide.

###